ORMP vs. ORGO, AURA, KALV, VALN, PRME, ETON, ENGN, KRRO, GLUE, and RGNX
Should you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Organogenesis (ORGO), Aura Biosciences (AURA), KalVista Pharmaceuticals (KALV), Valneva (VALN), Prime Medicine (PRME), Eton Pharmaceuticals (ETON), enGene (ENGN), Korro Bio (KRRO), Monte Rosa Therapeutics (GLUE), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.
Oramed Pharmaceuticals vs.
Organogenesis (NASDAQ:ORGO) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.
Organogenesis presently has a consensus target price of $5.00, suggesting a potential upside of 49.70%. Given Organogenesis' stronger consensus rating and higher probable upside, equities analysts plainly believe Organogenesis is more favorable than Oramed Pharmaceuticals.
49.6% of Organogenesis shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 36.9% of Organogenesis shares are held by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Oramed Pharmaceuticals has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Oramed Pharmaceuticals' return on equity.
In the previous week, Organogenesis and Organogenesis both had 2 articles in the media. Oramed Pharmaceuticals' average media sentiment score of 0.72 beat Organogenesis' score of 0.33 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.
Oramed Pharmaceuticals received 222 more outperform votes than Organogenesis when rated by MarketBeat users. Likewise, 73.00% of users gave Oramed Pharmaceuticals an outperform vote while only 66.44% of users gave Organogenesis an outperform vote.
Organogenesis has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.
Oramed Pharmaceuticals has lower revenue, but higher earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Organogenesis beats Oramed Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Oramed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oramed Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ORMP) was last updated on 1/21/2025 by MarketBeat.com Staff
